1 序文
2 調査範囲と方法論
2.1 調査の目的
2.2 ステークホルダー
2.3 データソース
2.3.1 一次情報源
2.3.2 二次情報源
2.4 市場推定
2.4.1 ボトムアップ・アプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法
3 エグゼクティブ・サマリー
4 はじめに
4.1 概要
4.2 主要業界動向
5 世界の新型インフルエンザワクチン市場
5.1 市場概要
5.2 市場パフォーマンス
5.3 COVID-19の影響
5.4 ワクチンタイプ別内訳
5.5 市場タイプ別内訳
5.6 主要ブランドの分析
5.7 地域別構成比
5.8 市場予測
6 ワクチンタイプ別市場内訳
6.1 筋肉内注射
6.1.1 市場動向
6.1.2 市場予測
6.2 経鼻
6.2.1 市場動向
6.2.2 市場予測
6.3 皮内
6.3.1 市場動向
6.3.2 市場予測
7 タイプ別市場
7.1 パブリック
7.1.1 市場動向
7.1.2 市場予測
7.2 プライベート
7.2.1 市場動向
7.2.2 市場予測
8 地域別市場内訳
8.1 北米
8.1.1 市場動向
8.1.2 市場予測
8.2 欧州
8.2.1 市場動向
8.2.2 市場予測
8.3 アジア太平洋
8.3.1 市場動向
8.3.2 市場予測
8.4 中東・アフリカ
8.4.1 市場動向
8.4.2 市場予測
8.5 中南米
8.5.1 市場動向
8.5.2 市場予測
9 主要ブランドの分析
9.1 アグリパール
9.2 フィアリックス
9.3 インフルゲン
9.4 インフルバック
9.5 ナソバック
9.6 ヴァキシグリップ
9.7 その他
10 SWOT分析
10.1 概要
10.2 長所
10.3 弱点
10.4 機会
10.5 脅威
11 バリューチェーン分析
12 ポーターズファイブフォース分析
12.1 概要
12.2 買い手の交渉力
12.3 供給者の交渉力
12.4 競争の程度
12.5 新規参入の脅威
12.6 代替品の脅威
13 価格分析
13.1 価格指標
13.2 価格構造
13.3 マージン分析
14 業界の動向
14.1 パイプラインと新製品上市
14.2 M&Aとパートナーシップ
15 競争環境
15.1 市場構造
15.2 主要プレイヤー
15.3 主要プレーヤーのプロフィール
15.3.1 アボット・ラボラトリーズ
15.3.1.1 会社概要
15.3.1.2 製品ポートフォリオ
15.3.1.3 財務
15.3.1.4 SWOT分析
15.3.2 アストラゼネカ plc
15.3.2.1 会社概要
15.3.2.2 製品ポートフォリオ
15.3.2.3 財務
15.3.2.4 SWOT分析
15.3.3 CPL Biologicals Pvt.
15.3.3.1 会社概要
15.3.3.2 製品ポートフォリオ
15.3.4 CSLリミテッド
15.3.4.1 会社概要
15.3.4.2 製品ポートフォリオ
15.3.4.3 財務
15.3.4.4 SWOT分析
15.3.5 ゾエティス・インク
15.3.5.1 会社概要
15.3.5.2 製品ポートフォリオ
15.3.5.3 財務
15.3.5.4 SWOT分析
図1：世界：新型インフルエンザワクチン市場：主な推進要因と課題
図2：世界：新型インフルエンザワクチン市場：売上額（単位：億ドル）、2019年～2024年
図3：世界：新型インフルエンザワクチン市場図3：新型インフルエンザワクチンの世界市場：ワクチンタイプ別構成比（単位：%）、2024年
図4：新型インフルエンザワクチンの世界市場：ワクチンタイプ別構成比（単位：%）、2024年タイプ別構成比（%）、2024年
図5：新型インフルエンザワクチンの世界市場：タイプ別構成比（%）、2024年地域別構成比（%）、2024年
図6: 世界の新型インフルエンザワクチン産業：SWOT分析
図7: 世界の新型インフルエンザワクチン産業：SWOT分析バリューチェーン分析
図8: 世界: 新型インフルエンザワクチン産業：ポーターのファイブフォース分析
図9: 世界の新型インフルエンザワクチン市場予測：販売額（単位：億ドル）、2025年-2033年
図10: 世界のH1N1ワクチン（筋肉内）市場：販売額（単位：百万USドル）、2019年・2024年
図11：世界のH1N1ワクチン（筋肉内）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図12: 世界のH1N1ワクチン（経鼻）市場: 2025-2033販売額（単位：百万ドル）、2019年および2024年
図13：世界の新型インフルエンザワクチン（経鼻）市場予測：販売額（単位：百万ドル）、2025年～2033年
図14: 世界のH1N1ワクチン（経皮）市場：売上額（単位：百万ドル販売額（単位：百万ドル）、2019年・2024年
図15：世界の新型インフルエンザワクチン（皮内）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図16: H1N1ワクチン（一般用）の世界市場：売上金額（単位：百万USドル販売額（単位：百万ドル）、2019年および2024年
図17：新型インフルエンザワクチン（一般用）の世界市場予測：販売額（単位：百万ドル）、2025年～2033年
図18: 新型インフルエンザワクチン（民間）世界市場：売上金額（単位：百万USドル販売額（単位：百万USドル）、2019年・2024年
図19：新型インフルエンザワクチン（民間）の世界市場予測：販売額（単位：百万ドル）、2025年～2033年
図20: 北米: 新型インフルエンザワクチン市場：売上金額（単位：百万USドル）、2019年・2024年
図21: 北米: 新型インフルエンザワクチン市場予測：販売額（百万ドル）、2025年～2033年
図22: 欧州: 新型インフルエンザワクチン市場：売上金額（単位：百万USドル）、2019年・2024年
図23: 欧州：新型インフルエンザワクチン市場予測：販売額（百万ドル）、2025年～2033年
図24：アジア太平洋地域：新型インフルエンザワクチン市場販売額（単位：百万ドル）、2019年および2024年
図25：アジア太平洋地域：新型インフルエンザワクチン市場予測：販売額（単位：百万ドル）、2025年～2033年
図26：中東・アフリカ：新型インフルエンザワクチン市場：販売額（単位：百万USドル）、2019年および2024年
図27：中東・アフリカ：新型インフルエンザワクチン市場予測：販売額（百万ドル）、2025年～2033年
図28：中南米：新型インフルエンザワクチン市場：販売額（単位：百万USドル）、2019年および2024年
図29：中南米：新型インフルエンザワクチン市場予測：販売額（単位：百万米ドル）、2025年～2033年
[表一覧］
表1：世界：新型インフルエンザワクチン市場：主要産業ハイライト、2024年および2033年
表2：新型インフルエンザワクチンの世界市場予測：ワクチンタイプ別内訳（単位：百万ドル）、2025年〜2033年
表3：新型インフルエンザワクチンの世界市場予測：タイプ別構成比（単位：百万ドル）、2025-2033年
表4：新型インフルエンザワクチンの世界市場予測：地域別構成比（単位：百万ドル）、2025-2033年
表5：新型インフルエンザワクチンの世界市場構造
表6：新型インフルエンザワクチンの世界市場：主要プレイヤー
The global H1N1 vaccines market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.03% during 2025-2033. The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market.
H1N1 vaccines, also known as influenza A (H1N1) vaccines, are designed to provide protection against the H1N1 strain of the influenza virus. This strain, commonly referred to as ""swine flu,"" caused a global pandemic in 2009. H1N1 vaccines contain inactivated or weakened forms of the virus or its components, prompting the immune system to produce antibodies against the H1N1 strain. These vaccines help prevent infection and mitigate the spread of the virus. They are typically included in seasonal flu vaccine formulations to offer immunity against H1N1 along with other prevalent influenza strains.
The ongoing threat of influenza pandemics underscores the importance of effective vaccines to prevent the spread of the H1N1 virus which represents one of the key factors driving the growth of the H1N1 vaccines market across the globe. High transmission rates and the potential for severe illness drive the demand for vaccines to safeguard public health. The increasing awareness about vaccination benefits and government initiatives to promote immunization programs amplify vaccine adoption which is further contributing to the market growth. Public health campaigns and educational efforts also contribute to higher vaccination rates. Additionally, the global interconnectedness of populations intensifies the need for preventive measures. International travel and trade facilitate the rapid spread of infectious diseases, necessitating robust vaccination strategies. Furthermore, collaborations between pharmaceutical companies, research institutions, and health organizations drive innovation and ensure timely vaccine development. Regulatory support and streamlined approval processes encourage investment in vaccine research and production which is creating a positive outlook for the market across the globe.
H1N1 Vaccines Market Trends/Drivers:
Rise in pandemic preparedness
The rising threat of future pandemics drives governments, healthcare organizations, and individuals to prioritize vaccination as a preventive measure, which is driving the growth of the market. The increasing need to minimize disease transmission and protect vulnerable populations is fueling the demand for H1N1 vaccines. This, along with improving healthcare infrastructure and increasing healthcare budgets by governments of various nations is contributing to the market growth.
Rising public health initiatives
Governments and health authorities worldwide are increasingly launching public health campaigns to promote vaccination and raise awareness about the benefits of H1N1 vaccines which is influencing the market growth. These initiatives focus on educating the public, dispelling myths, and encouraging proactive vaccination to ensure widespread protection against the virus. These campaigns contribute to higher vaccine uptake rates and improved community immunity. Governments of various nations are also focused on improving public healthcare facilities, making them accessible to even the remotest regions and to the marginalized sections, which is facilitating the uptake of the vaccines.
Rise in global travel and connectivity
Increased international travel and connectivity facilitate the rapid spread of infectious diseases like H1N1 which is further propelling the demand for H1N1 vaccines. The interconnectedness of global populations emphasizes the importance of population-level immunity to curb transmission. H1N1 vaccines play a vital role in reducing the potential for cross-border outbreaks by offering protection to travelers and reducing the risk of importation and subsequent transmission.
H1N1 Vaccines Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global H1N1 vaccines market report, along with forecasts at the global and regional levels from 2025-2033. Our report has categorized the market based on vaccine type, key brands and market type.
Breakup by Vaccine Type:
• Intramuscular
• Intranasal
• Intradermal
The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes intramuscular, intranasal, and intradermal. According to the report, intramuscular represented the largest segment.
Intramuscular vaccines hold a proven track record of eliciting strong and durable immune responses. The muscle tissue provides an optimal environment for antigen presentation, which leads to effective immune activation and antibody production. This enhances the vaccine's ability to confer protection against H1N1 and other influenza strains. Intramuscular injections are a well-established and familiar method in healthcare settings. Healthcare professionals are experienced in administering vaccines via this route, ensuring accurate dosing and proper delivery. The IM route is suitable for a wide range of age groups, from children to adults. This universality makes IM-administered H1N1 vaccines versatile and applicable in mass vaccination campaigns. Intramuscular injections are commonly associated with vaccination, contributing to public acceptance. People are accustomed to receiving vaccines in this manner, leading to fewer barriers and higher compliance rates.
Breakup by Market Type:
• Public
• Private
A detailed breakup and analysis of the market based on the market type has also been provided in the report. This includes public and private. According to the report, public accounted for the largest market share.
H1N1 vaccines serve crucial roles in public health by providing protection against the H1N1 strain of influenza virus. They help prevent widespread outbreaks by building population immunity, reducing the virus's transmission potential. This safeguards vulnerable individuals, such as the elderly, young children, and those with compromised immune systems. H1N1 vaccines minimize illness severity and related complications, reducing hospitalizations, medical costs, and the burden on healthcare systems. By preventing severe cases, vaccines contribute to overall public health and well-being. The widespread H1N1 vaccination efforts contribute to community immunity or herd immunity, indirectly protecting those who cannot be vaccinated due to medical reasons. This collaborative defense limits the virus's spread within the population. Furthermore, H1N1 vaccines play a pivotal role in pandemic preparedness, as they form the foundation for rapid response to emerging influenza strains with pandemic potential.
Breakup by Region:
• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America
The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.
In North America, the H1N1 vaccines market is driven by factors, including proactive public health initiatives, well-established vaccination programs, and a strong healthcare infrastructure. The memory of past outbreaks and pandemics, such as the 2009 H1N1 pandemic, has heightened awareness about the importance of vaccination. Robust healthcare systems, accessible medical facilities, and high levels of health literacy contribute to a culture of vaccination. Additionally, government support, regulatory frameworks, and public-private partnerships facilitate timely vaccine development, distribution, and administration. These factors collectively promote the demand for H1N1 vaccines, ensuring preparedness and protection against influenza outbreaks in North America.
Competitive Landscape:
Key players in the H1N1 vaccines market are actively engaged in several strategic initiatives to address the demand for effective vaccines and ensure public health preparedness. These companies focus on continuous research and development (R&D) to create vaccines with enhanced immunogenicity and broader coverage against H1N1 and related strains. Collaborations with research institutions and health authorities enable them to stay informed about evolving virus strains and pandemic potential. Moreover, key players invest in production scalability and efficiency to meet demand during outbreaks. They work closely with regulatory agencies to ensure vaccine safety, efficacy, and timely approvals. In addition, these companies engage in public health advocacy, promoting vaccination through education and awareness campaigns. Furthermore, collaborations with global health organizations, governments, and non-profit entities ensure equitable vaccine distribution, especially in regions with limited access to healthcare. By prioritizing innovation, safety, and accessibility, key players contribute to effective disease prevention and control in the H1N1 vaccines market.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
• Abbott Laboratories
• AstraZeneca plc
• CPL Biologicals Pvt. Ltd
• CSL Limited
• Zoetis Inc.
Key Questions Answered in This Report
1.What was the size of the global H1N1 vaccines market in 2024?
2.What is the expected growth rate of the global H1N1 vaccines market during 2025-2033?
3.What are the key factors driving the global H1N1 vaccines market?
4.What has been the impact of COVID-19 on the global H1N1 vaccines market?
5.What is the breakup of the global H1N1 vaccines market based on the vaccine type?
6.What is the breakup of the global H1N1 vaccines market based on the market type?
7.What are the key regions in the global H1N1 vaccines market?
